Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by Solid1on Apr 05, 2023 5:45am
312 Views
Post# 35380331

FDA approval

FDA approval
if I understand correctly, inspections were carried out by the FDA in the last Q!? 
 
I have a listing here 
 
Simplified representation of the testing process for drugs

1. animal testing
 
2. investigational new drug application (IND) with proposals for testing in humans
 
3. phase 1 studies in humans (usually with a group of 20 to 80 test subjects)
 
4. phase 2 human trials (usually with a group of up to 300 subjects)
 
5. phase 3 studies in humans (usually with a number of several hundred up to 3,000 test subjects)
 
6. time period before submission of a New Drug Application (NDA); time for meetings between FDA representatives and manufacturers of a new drug product
 
7. submission of the NDA - official step and question to the FDA to approve the drug for the U.S. market
 
8. FDA has 60 days to decide whether to accept the NDA (file) so that the application can then be reviewed (review).
 
9. if the FDA accepts the application, it assigns a staff team to review the manufacturer's research on the safety and efficacy of the drug.
 
10. the FDA reviews the labeling and package insert information submitted to it.
 
11. FDA conducts inspections of the manufacturer's facilities.
 
12. FDA staff approves the NDA (approval letter) or rejects it with a "complete response letter."

The source is on a German website:

https://www.gtai.de/de/trade/usa/zoll/standardpruefung-des-antrags-dauert-etwa-zehn-monate-582246
<< Previous
Bullboard Posts
Next >>